Jeffery Tessem

Dr. Jeffery Tessem

Brigham Young University
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Cells
Verified
Journal Article
Open access
PDF file
JHJacob Herring
Jacob Herring
WEWeston Elison
Weston Elison
Jeffery TessemJeffery Tessem
Jeffery Tessem
The Nr4a family of nuclear hormone receptors is composed of three members—Nr4a1/Nur77, Nr4a2/Nurr1 and Nr4a3/Nor1. While currently defined as ligandless, these transcription factors have been shown to regulate varied processes across a host of tissues. Of particular interest, the Nr4a family impinge, in a tissue dependent fashion, on cellular proliferation, apoptosis and fuel utilization. The regulation of these processes occurs through both nuclear and non-genomic pathways. The purpose of this review is to provide a balanced perspective of the tissue specific and Nr4a family member specific, effects on cellular proliferation, apoptosis and fuel utilization.

1 May 2008 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
JSJonathan C Schisler
Jonathan C Schisler
PFPatrick T. Fueger
Patrick T. Fueger
DBDaniella A. Babu
Daniella A. Babu
HHHans E. Hohmeier
Hans E. Hohmeier
Jeffery TessemJeffery Tessem
Jeffery Tessem
CNChristopher B. Newgard
Christopher B. Newgard
The homeodomain transcription factor Nkx6.1 plays an important role in pancreatic islet beta-cell development, but its effects on adult beta-cell function, survival, and proliferation are not well understood. In the present study, we demonstrated that treatment of primary rat pancreatic islets with a cytomegalovirus promoter-driven recombinant adenovirus containing the Nkx6.1 cDNA (AdCMV-Nkx6.1) causes dramatic increases in [methyl-(3)H] thymidine and 5-bromo-2'-deoxyuridine (BrdU) incorporation and in the number of cells per islet relative to islets treated with a control adenovirus (AdCMV-betaGAL), whereas suppression of Nkx6.1 expression reduces thymidine incorporation. Immunocytochemical studies reveal that >80% of BrdU-positive cells in AdCMV-Nkx6.1-treated islets are beta cells. Microarray, real-time PCR, and immunoblot analyses reveal that overexpression of Nkx6.1 in rat islets causes concerted upregulation of a cadre of cell cycle control genes, including those encoding cyclins A, B, and E, and several regulatory kinases. Cyclin E is upregulated earlier than the other cyclins, and adenovirus-mediated overexpression of cyclin E is shown to be sufficient to activate islet cell proliferation. Moreover, chromatin immunoprecipitation assays demonstrate direct interaction of Nkx6.1 with the cyclin A2 and B1 genes. Overexpression of Nkx6.1 in rat islets caused a clear enhancement of glucose-stimulated insulin secretion (GSIS), whereas overexpression of Nkx6.1 in human islets caused an increase in the level of [(3)H]thymidine incorporation that was twice the control level, along with complete retention of GSIS. We conclude that Nkx6.1 is among the very rare factors capable of stimulating beta-cell replication with retention or enhancement of function, properties that may be exploitable for expansion of beta-cell mass in treatment of both major forms of diabetes.

24 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Jeffery TessemJeffery Tessem
Jeffery Tessem
LMLarry G. Moss
Larry G. Moss
LCLily C. Chao
Lily C. Chao
MAMichelle Arlotto
Michelle Arlotto
DLDanhong Lu
Danhong Lu
CNChristopher B. Newgard
Christopher B. Newgard
Significance: Loss of pancreatic islet β cells occurs in both major forms of diabetes, and strategies for restoring β cells are needed. The homeobox transcription factor NK6 homeobox 1 (Nkx6.1) activates β-cell proliferation and insulin secretion when overexpressed in pancreatic islets, but the molecular pathway involved in the proliferative response is unknown. We show that Nkx6.1 induces expression of orphan nuclear receptor subfamily 4, group A, members 1 and 3 (Nr4a1 and Nr4a3), which stimulate proliferation via two mechanisms: ( i ) increased expression of the cell cycle inducers E2F transcription factor 1 and cyclin E1; and ( ii ) induction of anaphase-promoting complex elements, and degradation of the cell cycle inhibitor p21. These studies reveal a new bipartite pathway for activation of β-cell proliferation that could guide development of therapeutic strategies for diabetes.

1 September 2016 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
KSKaren M. Strat
Karen M. Strat
TRThomas J. Rowley
Thomas J. Rowley
ASAndrew T. Smithson
Andrew T. Smithson
Jeffery TessemJeffery Tessem
Jeffery Tessem
MHMatthew W. Hulver
Matthew W. Hulver
ANAndrew Neilson
Andrew Neilson

17 October 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
FLFeng X. Li
Feng X. Li
JZJing W. Zhu
Jing W. Zhu
Jeffery TessemJeffery Tessem
Jeffery Tessem
JBJoshua Beilke
Joshua Beilke
MVMarileila Varella-Garcia
Marileila Varella-Garcia
JDJames DeGregori
James DeGregori
Our studies of mice deficient for the E2F1 and E2F2 transcription factors have revealed essential roles for these proteins in the cell cycle control of pancreatic exocrine cells and the regulation of pancreatic beta cell maintenance. Pancreatic exocrine cells in E2f1/E2f2 mutant mice become increasingly polyploid with age, coinciding with severe exocrine atrophy. Furthermore, mice deficient for both E2F1 and E2F2 develop nonautoimmune, insulin-dependent diabetes with high penetrance. Surprisingly, transplantation of wild-type bone marrow can prevent or rescue diabetes in E2f1 -/- E2f2 -/- mice. We hypothesize that exocrine degeneration results in a destructive environment for beta cells, which can be alleviated by restoration of the hematopoietic system that is also defective in E2f1 -/- E2f2 -/- mice. The demonstration that beta cell maintenance under conditions of stress is influenced by bone marrow-derived cells may provide important insight into the design of therapies to boost islet mass and function in diabetic patients.

1 November 2017 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
TRThomas J. Rowley
Thomas J. Rowley
BBBenjamin F. Bitner
Benjamin F. Bitner
JRJason D. Ray
Jason D. Ray
DLDaniel Lathen
Daniel Lathen
ASAndrew T. Smithson
Andrew T. Smithson
Jeffery TessemJeffery Tessem
Jeffery Tessem